330 related articles for article (PubMed ID: 10936140)
1. Soluble form of fas and fas ligand in BAL fluid from patients with pulmonary fibrosis and bronchiolitis obliterans organizing pneumonia.
Kuwano K; Kawasaki M; Maeyama T; Hagimoto N; Nakamura N; Shirakawa K; Hara N
Chest; 2000 Aug; 118(2):451-8. PubMed ID: 10936140
[TBL] [Abstract][Full Text] [Related]
2. Increased circulating levels of soluble Fas ligand are correlated with disease activity in patients with fibrosing lung diseases.
Kuwano K; Maeyama T; Inoshima I; Ninomiya K; Hagimoto N; Yoshimi M; Fujita M; Nakamura N; Shirakawa K; Hara N
Respirology; 2002 Mar; 7(1):15-21. PubMed ID: 11896896
[TBL] [Abstract][Full Text] [Related]
3. The involvement of Fas-Fas ligand pathway in fibrosing lung diseases.
Kuwano K; Miyazaki H; Hagimoto N; Kawasaki M; Fujita M; Kunitake R; Kaneko Y; Hara N
Am J Respir Cell Mol Biol; 1999 Jan; 20(1):53-60. PubMed ID: 9870917
[TBL] [Abstract][Full Text] [Related]
4. Interleukin 5 and granulocyte-macrophage colony-stimulating factor levels in bronchoalveolar lavage fluid in interstitial lung disease.
Taniguchi H; Katoh S; Kadota J; Matsubara Y; Fukushima K; Mukae H; Matsukura S; Kohno S
Eur Respir J; 2000 Nov; 16(5):959-64. PubMed ID: 11153599
[TBL] [Abstract][Full Text] [Related]
5. Soluble form of Fas and Fas ligand in serum and bronchoalveolar lavage fluid of individuals infected with human T-lymphotropic virus type 1.
Sakamoto N; Mukae H; Fujii T; Kakugawa T; Kaida H; Kadota J; Kohno S
Respir Med; 2004 Mar; 98(3):213-9. PubMed ID: 15002756
[TBL] [Abstract][Full Text] [Related]
6. Expression of FasL and Fas protein and their soluble form in patients with hypersensitivity pneumonitis.
Kuwano K; Hagimoto N; Kawasaki M; Nakamura N; Shirakawa K; Maeyama T; Hara N
Int Arch Allergy Immunol; 2000 Jul; 122(3):209-15. PubMed ID: 10899765
[TBL] [Abstract][Full Text] [Related]
7. S100A9 in BALF is a candidate biomarker of idiopathic pulmonary fibrosis.
Hara A; Sakamoto N; Ishimatsu Y; Kakugawa T; Nakashima S; Hara S; Adachi M; Fujita H; Mukae H; Kohno S
Respir Med; 2012 Apr; 106(4):571-80. PubMed ID: 22209187
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of MCP-1 levels in BALF and serum in patients with interstitial lung diseases.
Suga M; Iyonaga K; Ichiyasu H; Saita N; Yamasaki H; Ando M
Eur Respir J; 1999 Aug; 14(2):376-82. PubMed ID: 10515417
[TBL] [Abstract][Full Text] [Related]
9. B7-1, B7-2 and class II MHC molecules in idiopathic pulmonary fibrosis and bronchiolitis obliterans-organizing pneumonia.
Kaneko Y; Kuwano K; Kunitake R; Kawasaki M; Hagimoto N; Hara N
Eur Respir J; 2000 Jan; 15(1):49-55. PubMed ID: 10678620
[TBL] [Abstract][Full Text] [Related]
10. Differential role of the Fas/Fas ligand apoptotic pathway in inflammation and lung fibrosis associated with reovirus 1/L-induced bronchiolitis obliterans organizing pneumonia and acute respiratory distress syndrome.
Lopez AD; Avasarala S; Grewal S; Murali AK; London L
J Immunol; 2009 Dec; 183(12):8244-57. PubMed ID: 20007588
[TBL] [Abstract][Full Text] [Related]
11. The evaluation of soluble Fas and soluble Fas ligand levels of bronchoalveolar lavage fluid in lung cancer patients.
Erdoğan B; Uzaslan E; Budak F; Karadağ M; Ediger D; Oral B; Göral G; Ege E; Gözü O
Tuberk Toraks; 2005; 53(2):127-31. PubMed ID: 16100648
[TBL] [Abstract][Full Text] [Related]
12. CCL18 in serum, BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseases.
Cai M; Bonella F; He X; Sixt SU; Sarria R; Guzman J; Costabel U
Respir Med; 2013 Sep; 107(9):1444-52. PubMed ID: 23831213
[TBL] [Abstract][Full Text] [Related]
13. Increase of activated T-cells in BAL fluid of Japanese patients with bronchiolitis obliterans organizing pneumonia and chronic eosinophilic pneumonia.
Mukae H; Kadota J; Kohno S; Matsukura S; Hara K
Chest; 1995 Jul; 108(1):123-8. PubMed ID: 7606945
[TBL] [Abstract][Full Text] [Related]
14. Idiopathic nonspecific interstitial pneumonia/fibrosis: comparison with idiopathic pulmonary fibrosis and BOOP.
Nagai S; Kitaichi M; Itoh H; Nishimura K; Izumi T; Colby TV
Eur Respir J; 1998 Nov; 12(5):1010-9. PubMed ID: 9863989
[TBL] [Abstract][Full Text] [Related]
15. Enhanced expression of Fas Ligand (FasL) in the lower airways of patients with fibrotic interstitial lung diseases (ILDs).
Kopiński P; Balicka-Ślusarczyk B; Dyczek A; Szpechciński A; Przybylski G; Jarzemska A; Wandtke T; Jankowski M; Iwaniec T; Chorostowska-Wynimko J
Folia Histochem Cytobiol; 2011; 49(4):636-45. PubMed ID: 22252758
[TBL] [Abstract][Full Text] [Related]
16. Characteristic elevation of matrix metalloproteinase activity in idiopathic interstitial pneumonias.
Suga M; Iyonaga K; Okamoto T; Gushima Y; Miyakawa H; Akaike T; Ando M
Am J Respir Crit Care Med; 2000 Nov; 162(5):1949-56. PubMed ID: 11069839
[TBL] [Abstract][Full Text] [Related]
17. Classification and recent advances in idiopathic interstitial pneumonia.
Nagai S; Kitaichi M; Izumi T
Curr Opin Pulm Med; 1998 Sep; 4(5):256-60. PubMed ID: 10813199
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of the interleukin-10 gene by alveolar macrophages in interstitial lung disease.
Martinez JA; King TE; Brown K; Jennings CA; Borish L; Mortenson RL; Khan TZ; Bost TW; Riches DW
Am J Physiol; 1997 Sep; 273(3 Pt 1):L676-83. PubMed ID: 9316504
[TBL] [Abstract][Full Text] [Related]
19. Comparison of BALF concentrations of ENA-78 and IP10 in patients with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia.
Nakayama S; Mukae H; Ishii H; Kakugawa T; Sugiyama K; Sakamoto N; Fujii T; Kadota J; Kohno S
Respir Med; 2005 Sep; 99(9):1145-51. PubMed ID: 16085216
[TBL] [Abstract][Full Text] [Related]
20. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in advanced melanoma.
Mouawad R; Khayat D; Soubrane C
Melanoma Res; 2000 Oct; 10(5):461-7. PubMed ID: 11095407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
